Cargando…

Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy

Trametinib, a selective inhibitor of mitogen‐activated protein kinase kinase 1 (MEK1) and MEK2, significantly improves progression‐free survival compared with chemotherapy in patients with BRAF V600E/K mutation–positive advanced or metastatic melanoma (MM). However, the pivotal clinical trial permit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Latimer, Nicholas R., Bell, Helen, Abrams, Keith R., Amonkar, Mayur M., Casey, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864810/ https://www.ncbi.nlm.nih.gov/pubmed/27172483 http://dx.doi.org/10.1002/cam4.643

Ejemplares similares

Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
por: Skaltsa, Konstantina, et al.
Publicado: (2016)

Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring
por: Latimer, N. R., et al.
Publicado: (2019)

Evaluation of methods to adjust for treatment switching in clinical trials
por: Fox, Richard, et al.
Publicado: (2011)

Trametinib therapy for children with neurofibromatosis type 1 and life‐threatening plexiform neurofibroma or treatment‐refractory low‐grade glioma
por: Ronsley, Rebecca, et al.
Publicado: (2021)

Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma
por: Zhou, Xiaohan, et al.
Publicado: (2021)

Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study
por: Morden, James P, et al.
Publicado: (2011)

Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer
por: Wang, Qing, et al.
Publicado: (2021)

A hypoxia-related prognostic model predicts overall survival and treatment response in hepatocellular carcinoma
por: Xing, Jiyuan, et al.
Publicado: (2022)

Uronic acid metabolic process–related gene expression–based signature predicts overall survival of glioma
por: Feng, Yuemei, et al.
Publicado: (2021)

Strategies for selecting/switching chemotherapy and supportive care treatments during COVID‐19 outbreak
por: Li, Quan, et al.
Publicado: (2020)

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies
por: Patel, Gargi S, et al.
Publicado: (2015)

Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer
por: Lee, Shu‐Hui, et al.
Publicado: (2019)

Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
por: Johnson, Benny, et al.
Publicado: (2022)

Further improvement of our metrics—will plan S affect them?
por: Andersson, Arne, et al.
Publicado: (2019)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2020)

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
por: Tawbi, Hussein A, et al.
Publicado: (2022)

Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression
por: van den Bulk, Jitske, et al.
Publicado: (2021)

Referral process to further evaluate poor sleep in breast cancer survivors
por: Otte, Julie L., et al.
Publicado: (2022)

Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding
por: Latimer, NR, et al.
Publicado: (2020)

Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study
por: Omland, Lise H., et al.
Publicado: (2020)

Oral hygiene and the overall survival of head and neck cancer patients
por: Chang, Chan‐Chi, et al.
Publicado: (2019)

Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis
por: Watts, Eleanor L, et al.
Publicado: (2022)

Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017)

High impact of macroaggregated albumin‐based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90)Y‐loaded glass microsphere radioembolization
por: Garin, Etienne, et al.
Publicado: (2016)

Bayesian forecasting of tumor size metrics and overall survival
por: Krishnan, Sreenath M., et al.
Publicado: (2022)

Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis
por: Ghali, Fady, et al.
Publicado: (2022)

Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple‐negative breast cancer
por: Heeg, Erik, et al.
Publicado: (2019)

Association between patient‐initiated emails and overall 2‐year survival in cancer patients undergoing chemotherapy: Evidence from the real‐world setting
por: Coquet, Jean, et al.
Publicado: (2020)

OTHR-39. Extraneural spreading of a diffuse leptomeningeal glioneuronal tumor in a child: patient-derived models show sensitivity to vinblastin and trametinib
por: Messiaen, Julie, et al.
Publicado: (2022)

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study
por: Feyerabend, Susan, et al.
Publicado: (2019)

Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study
por: Di Scala, Lilla, et al.
Publicado: (2022)

The prediction models for postoperative overall survival and disease‐free survival in patients with breast cancer
por: Shigemizu, Daichi, et al.
Publicado: (2017)

Q-switched Nd:YAG Laser to Treat Nevomelanocytic Nevi
por: Parasramani, SG, et al.
Publicado: (2009)

Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma
por: Naso, Julia R., et al.
Publicado: (2020)

Over-Adjustment Bias by Controlling for Overall Health
por: Assari, Shervin
Publicado: (2013)

Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer
por: Adams, Christina R, et al.
Publicado: (2019)

Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
por: Latimer, NR, et al.
Publicado: (2018)

PIAS3 expression in squamous cell lung cancer is low and predicts overall survival
por: Abbas, Rime, et al.
Publicado: (2015)

A survey of overall life satisfaction and its association with breast diseases in Chinese women
por: Bai, Aili, et al.
Publicado: (2015)

Overall Survival of Breast Cancer Patients With Locoregional Failures Involving Internal Mammary Nodes
por: Xu, Amy J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s3o8mv224794obp2ig33dhnb2p